Skip to content
10-K

Annual Report

TriSalus Life Sciences, Inc. TLSI TLSIW

0001628280-26-015163

← back to feed
Filed
Mar 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 2, 2026 61.31M sh
Shares Diluted FY 2025 · Dec 31, 2025 37.9M sh
Capex FY 2025 · Dec 31, 2025 $918K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$18.01M
Long Term Debt FY 2025 · Dec 31, 2025 $33.05M
Cash And Equivalents FY 2025 · Dec 31, 2025 $20.44M
Stockholders Equity FY 2025 · Dec 31, 2025 −$33.86M
Current Liabilities FY 2025 · Dec 31, 2025 $11.5M
Total Liabilities FY 2025 · Dec 31, 2025 $69.19M
Current Assets FY 2025 · Dec 31, 2025 $32.24M
Total Assets FY 2025 · Dec 31, 2025 $35.33M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.84
Eps Basic FY 2025 · Dec 31, 2025 −$1.84
Sga Expense FY 2025 · Dec 31, 2025 $21.46M
Rd Expense FY 2025 · Dec 31, 2025 $14.97M
Net Income FY 2025 · Dec 31, 2025 −$39.23M
Operating Income FY 2025 · Dec 31, 2025 −$26.95M
Gross Profit FY 2025 · Dec 31, 2025 $38.19M
Cost Of Revenue FY 2025 · Dec 31, 2025 $6.97M
Revenue FY 2025 · Dec 31, 2025 $45.15M